Advanced Life Sciences' antibiotic gets US panel review
This article was originally published in Scrip
Executive Summary
Advanced Life Sciences' (ALS) novel antibiotic cethromycin will be reviewed by the US FDA's anti-infective drugs advisory committee on June 2nd. The proposed indication is out-patient treatment of adults with mild-to-moderate community-acquired pneumonia (CAP).